INSIGHT 01Fact
87%
87% of applications are in Pharmaceuticals
812 applications in this field, 760 of them in IPC A61K — the main axis of the portfolio.
Method: Field applications ÷ applications with IPC
Company patentsInnovative medicines and biopharmaceuticals
COMPANY PATENT INTELLIGENCE
Explore medicines, formulations and related technologies through publications attributed to selected Pfizer legal entities.
≥998docs
83 per month · peak 2025-03 (155)
Empty dashed outlines are uncollected periods, not zero. Dashed bars have partial name or date coverage.
INSIGHT 01Fact
87%
812 applications in this field, 760 of them in IPC A61K — the main axis of the portfolio.
Method: Field applications ÷ applications with IPC
934 applications with IPC codes are mapped to 35 fields using the WIPO IPC–Technology Concordance; area is the number of applications. Select a tile to see its IPC subclasses. An application can belong to several fields.
Publications per month in each field; brighter cells mean more. It shows which directions surge in particular months.
This chart covers collected documents published from 2025-01-01 to 2025-12-31. Examination and publication processes affect this timing; it does not directly measure R&D investment in the same period.
| Technology field | 25-01 | 25-02 | 25-03 | 25-04 | 25-05 | 25-06 | 25-07 | 25-08 | 25-09 | 25-10 | 25-11 | 25-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceuticals | 54 | 67 | 137 | 69 | 83 | 68 | 75 | 42 | 54 | 84 | 57 | 53 |
| Organic fine chemistry | 21 | 23 | 62 | 29 | 39 | 26 | 28 | 18 | 19 | 24 | 26 | 22 |
| Biotechnology | 24 | 35 | 57 | 28 | 31 | 22 | 26 | 16 | 24 | 31 | 14 | 15 |
| Medical technology | 4 | 3 | 5 | 3 | 3 | 2 | 7 | 3 | 4 | 3 | 4 | 0 |
| Chemical engineering | 3 | 3 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 |
| Analysis of biological materials | 0 | 1 | 2 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 2 | 1 |
| Macromolecular chemistry, polymers | 2 | 1 | 1 | 1 | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0 |
| Computer technology | 3 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 |
Documents in the current publication window are deduplicated by application number and grouped by filing year. These are not the company's complete annual filings; older applications may only be published or granted within this window.
Invention applications are generally published about 18 months after filing, or priority where claimed, and may be published earlier. Flags are estimated as of 2026-11-17. An unflagged year is still not necessarily complete; these counts cannot establish growth or contraction in R&D.
Multi-year evolution · With a longer collection window, this becomes a yearly view that marks the fastest-growing and shrinking fields.
Four reproducible structural ratios, with the other published companies on the same scale. Entity scopes and windows can differ, so read relative positions only — this is not a ranking.
Position 5 of 26 published companies.
Method: Sum of squared field shares
Position 9 of 26 published companies.
Method: Utility model documents ÷ all documents
The source has no CPC codes, so this cannot be computed.
Method: Documents with CPC Y02 ÷ documents with CPC
Position 16 of 26 published companies.
Method: Applications in measurement, chemical engineering, handling and machine tools ÷ all applications
Organisations that filed jointly with the collected entities; line weight represents joint applications. Name-based candidates and reviewed relationships are labeled separately. Co-applications alone do not prove ownership.
Possible affiliation is a review lead only. Co-applicants without a review record are not automatically group members or external partners, and their independent filings are not added to these statistics.
Review the entity listEntity review and data coverage are separate facts. This list shows the current entity configuration, evidence and relationship dates, matched name by name against this snapshot.
Filters change only the entity list below, not the statistics. A complete group snapshot is not available to switch to on this page.
Showing 1 of 1 entities
原始申请人示例将 PFIZER 与 PFIZER INC 对应到 Pfizer Inc.。未纳入 Seagen、惠氏及其他子公司独立名下文献。
Review evidenceRelationship dates help interpret renaming, acquisitions and joint ventures. Missing dates do not establish an indefinite relationship or verify the current patent owner.
Written by editors after reading the patent texts and company materials. Verified facts and inferences are labeled, each with evidence and limits.
Select a theme to filter reviewed patents and observations that cite them. Counts are editorial samples only; one patent may belong to several themes. They do not describe the full portfolio distribution.
Themes describe the technical directions in these samples. Links to adoption in specific products, commercialization or commercial value have not been established.
Showing 2 sample patents · 0 linked observations
Hand-picked documents that illustrate technology themes — not a ranking of core patents and not representative of the whole.
US20250000960A1
The abstract describes RNA encoding an E. coli FimH antigen and lipid-nanoparticle formulations. Claim 1 specifically requires a FimH-encoding open reading frame and a 5′ untranslated region with at least 90% identity to one of the listed sequences. Lipid nanoparticles appear in the abstract but are not a required element of this claim.
US20250009864A1
The abstract concerns pneumococcal capsular glycoconjugates. Claims 1–31 are marked cancelled in this publication, so the reading uses claim 32: a kit containing two immunogenic compositions, each including at least one glycoconjugate from its respective listed serotype group. The two at-least-one requirements do not require every listed serotype.
39 publication offices · 998 documents
Counts use the publication office of each collected document, retaining publications from the same family in different jurisdictions. This is not a map of complete families, granted or active rights; WO and EP denote international and European publication routes.
Invention grant
Method of treating COVID-19
PFIZER
Pharmaceuticals
Other
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PFIZER / BISHWA RAJ BHETUWAL / Kaushik Dutta / JIANXIN GU / SUNAYANA KAPIL / JIN HWAN KIM / JUSTIN KEITH MORAN / SUDDHAM SINGH / YUYING YANG
Pharmaceuticals
Other
Methods of treating hepatic-only metastatic uveal melanoma
IDEAYA BIOSCIENCES INC / PFIZER / MAURER MATTHEW ANTHONY / HATA YUJIRO / OQUIGLEY MICHAEL GABRIEL
Pharmaceuticals
Other
Compuestos de pirido[4,3-d]pirimidina
PFIZER
Organic fine chemistryPharmaceuticals
Other
Compuestos de derivados de ácido indazol propiónico sustituidos y usos de estos
PFIZER
Organic fine chemistryPharmaceuticals
Other
Antagonistas del receptor de polipéptido insulinotrópico dependiente de glucosa y usos de estos
PFIZER
Organic fine chemistryPharmaceuticals
Other
Benzisoxazole sulfonamide derivatives
PFIZER / CTXT PTY LTD
Organic fine chemistryPharmaceuticals
Invention publication
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PFIZER
Pharmaceuticals
Invention publication
Combination vaccine against coronavirus infection, influenza infection and/or RSV infection
BIOTECH EUROPE S A / PFIZER
Pharmaceuticals
Invention publication
Substituted indazole propionic acid derivative compounds and their use as AMPK activators
PFIZER
Organic fine chemistryPharmaceuticals
Invention publication
Anti-EDB antibodies and antibody-drug conjugates
PFIZER
BiotechnologyPharmaceuticals
Other
DLL3 targeting chimeric antigen receptors and binding agents
ALLOGENE THERAPEUTICS INC / PFIZER
BiotechnologyPharmaceuticals
Other
Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof
PFIZER
Organic fine chemistryPharmaceuticals
Invention publication
Methods of manufacturing a bifunctional compound
ARVINAS OPERATIONS INC / PFIZER
Organic fine chemistry
Invention publication
Ponsegromab for use in treating cachexia in cancer patients
PFIZER
BiotechnologyPharmaceuticals
Other
Composición farmacéutica en solución acuosa
PFIZER
Organic fine chemistryPharmaceuticals
Invention publication
Combination therapy comprising a pkc inhibitor and a c-met inhibitor
IDEAYA BIOSCIENCES INC / PFIZER
Organic fine chemistryPharmaceuticals
Invention publication
Vaccines against respiratory diseases
PFIZER
BiotechnologyPharmaceuticals
Invention publication
Immunogenic compositions and methods of inducing an immune response against varicella zoster virus
PFIZER
Pharmaceuticals
Other
Benzisoxazole sulfonamide derivatives
PFIZER / CTXT PTY LTD
Organic fine chemistryPharmaceuticals
Titles come from the source bibliography. Select a number to read the full document on this site.
Upload your invention disclosure and get an editable draft that follows CNIPA practice.
Publications are deduplicated by publication number; applications by application number, so a publication and its grant count once; families by the source family ID. Technology fields are derived automatically from IPC codes using the WIPO IPC–Technology Concordance (March 2026), without manual or AI labeling.
Publication or grant documents do not establish current rights. Check legal status and current owners with the relevant patent office.
These statistics use only the applicant names and publication dates collected for this snapshot. They do not represent the full company or group portfolio.
The reviewed entities and aliases below describe the current company configuration. Only names listed above are covered by this snapshot.
Pfizer Inc.
Configured aliases: PFIZER · PFIZER INC
Original review note: 原始申请人示例将 PFIZER 与 PFIZER INC 对应到 Pfizer Inc.。未纳入 Seagen、惠氏及其他子公司独立名下文献。
Review evidenceFound a wrong attribution or number? Tell us